The information in this section is intended for visitors outside the United States.
Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3
European CHMP Adopts Positive Opinion for Gilead Sciences’ Sovaldi® for the Treatment of Chronic Hepatitis C Infection
Gilead’s Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study
2012 Interactive Annual Report